Enhancing the Anti-tumor Potency of a Novel Siglec-15 Antibody by Engineering its Fc-mediated Effector Functions

Siglec-15, an inhibitory immune checkpoint, is an emerging target in cancer immunotherapy. Blocking the function of Siglec-15 is an excellent strategy for cancer treatment and antibody blockade has been used to target Siglec-15. However, whether Fc-mediated effector functions contribute to the thera...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Huandi, Yao, Bing, Ci, Lei, Feng, Jing, Ouyang, Pingkai, Chen, Guoguang, Hui, Xiwu, Zhou, Demin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Basic Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10168116/
https://www.ncbi.nlm.nih.gov/pubmed/37103472
http://dx.doi.org/10.1097/CJI.0000000000000465

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10168116/
https://www.ncbi.nlm.nih.gov/pubmed/37103472
http://dx.doi.org/10.1097/CJI.0000000000000465

Ejemplares similares